Xencor (NASDAQ:XNCR) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.15, Morningstar.com reports. The company had revenue of $19.49 million during the quarter, compared to the consensus estimate of $7.58 million.
Shares of NASDAQ XNCR traded down $9.27 during midday trading on Wednesday, hitting $37.00. 1,314,031 shares of the company’s stock were exchanged, compared to its average volume of 347,647. The company has a quick ratio of 6.66, a current ratio of 6.66 and a debt-to-equity ratio of 0.02. Xencor has a 12 month low of $27.75 and a 12 month high of $48.38. The business has a 50 day moving average of $42.49. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -28.24 and a beta of 1.39.
In other Xencor news, major shareholder John S. Stafford III bought 12,641 shares of Xencor stock in a transaction dated Thursday, June 6th. The stock was bought at an average cost of $29.87 per share, for a total transaction of $377,586.67. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 4.33% of the company’s stock.
A number of research analysts have weighed in on the company. Raymond James restated a “market perform” rating on shares of Xencor in a research note on Wednesday. Zacks Investment Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a research note on Saturday, July 20th. ValuEngine upgraded Xencor from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 2nd. Mizuho reiterated a “buy” rating and set a $52.00 target price on shares of Xencor in a research note on Monday, July 1st. Finally, BidaskClub upgraded Xencor from a “hold” rating to a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $44.35.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Recommended Story: What are different types of coverage ratios?
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.